Intervacc is trading at €0.05, down 19.11%, as no clear immediate catalyst has been identified. - No company-specific announcement explaining the September 28, 2026 decline was identified; the latest surfaced company release was a September 15 conference-participation notice. - Available evidence does not establish broader biotech weakness or macro sentiment as the cause. The supplied U.S. index readings are flat, while futures point to a softer but modest open.